Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

584 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical course and risk factors for mortality of COVID-19 patients with pre-existing cirrhosis: a multicentre cohort study.
Qi X, Liu Y, Wang J, Fallowfield JA, Wang J, Li X, Shi J, Pan H, Zou S, Zhang H, Chen Z, Li F, Luo Y, Mei M, Liu H, Wang Z, Li J, Yang H, Xiang H, Li X, Liu T, Zheng MH, Liu C, Huang Y, Xu D, Li X, Kang N, He Q, Gu Y, Zhang G, Shao C, Liu D, Zhang L, Li X, Kawada N, Jiang Z, Wang F, Xiong B, Takehara T, Rockey DC; COVID-Cirrhosis-CHESS Group. Qi X, et al. Among authors: kawada n. Gut. 2021 Feb;70(2):433-436. doi: 10.1136/gutjnl-2020-321666. Epub 2020 May 20. Gut. 2021. PMID: 32434831 Free PMC article. No abstract available.
Clinical course of COVID-19 in patients with pre-existing decompensated cirrhosis: initial report from China.
Qi X, Wang J, Li X, Wang Z, Liu Y, Yang H, Li X, Shi J, Xiang H, Liu T, Kawada N, Maruyama H, Jiang Z, Wang F, Takehara T, Rockey DC, Sarin SK; COVID-Cirrhosis-CHESS Group. Qi X, et al. Among authors: kawada n. Hepatol Int. 2020 Jul;14(4):478-482. doi: 10.1007/s12072-020-10051-z. Epub 2020 May 22. Hepatol Int. 2020. PMID: 32440857 Free PMC article.
Targeted and regulable expression of transgenes in hepatic stellate cells and myofibroblasts in culture and in vivo using an adenoviral Cre/loxP system to antagonise hepatic fibrosis.
Kinoshita K, Iimuro Y, Fujimoto J, Inagaki Y, Namikawa K, Kiyama H, Nakajima Y, Otogawa K, Kawada N, Friedman SL, Ikeda K. Kinoshita K, et al. Among authors: kawada n. Gut. 2007 Mar;56(3):396-404. doi: 10.1136/gut.2005.085704. Epub 2006 Sep 6. Gut. 2007. PMID: 16956920 Free PMC article.
Serum Fucosylated Haptoglobin as a Novel Diagnostic Biomarker for Predicting Hepatocyte Ballooning and Nonalcoholic Steatohepatitis.
Kamada Y, Akita M, Takeda Y, Yamada S, Fujii H, Sawai Y, Doi Y, Asazawa H, Nakayama K, Mizutani K, Fujii H, Yakushijin T, Miyazaki M, Ezaki H, Hiramatsu N, Yoshida Y, Kiso S, Imai Y, Kawada N, Takehara T, Miyoshi E. Kamada Y, et al. Among authors: kawada n. PLoS One. 2013 Jun 21;8(6):e66328. doi: 10.1371/journal.pone.0066328. Print 2013. PLoS One. 2013. PMID: 23805214 Free PMC article. Clinical Trial.
[Latest anti-fibrotic therapies for chronic liver diseases].
Sato-Matsubara M, Kawada N. Sato-Matsubara M, et al. Among authors: kawada n. Nihon Shokakibyo Gakkai Zasshi. 2020;117(1):52-63. doi: 10.11405/nisshoshi.117.52. Nihon Shokakibyo Gakkai Zasshi. 2020. PMID: 31941857 Japanese. No abstract available.
Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study.
Tahata Y, Hikita H, Mochida S, Kawada N, Enomoto N, Ido A, Yoshiji H, Miki D, Hiasa Y, Takikawa Y, Sakamori R, Kurosaki M, Yatsuhashi H, Tateishi R, Ueno Y, Itoh Y, Yamashita T, Kanto T, Suda G, Nakamoto Y, Kato N, Asahina Y, Matsuura K, Terai S, Nakao K, Shimizu M, Takami T, Akuta N, Yamada R, Kodama T, Tatsumi T, Yamada T, Takehara T. Tahata Y, et al. Among authors: kawada n. J Gastroenterol. 2021 Jan;56(1):67-77. doi: 10.1007/s00535-020-01733-4. Epub 2020 Oct 1. J Gastroenterol. 2021. PMID: 33001338 Clinical Trial.
584 results